Houston talk. Take it with you.Free KSEV Radio appGet for iPhoneGet for Android
Skip to content
KSEV 700 AM KSEV 700 AMThe Voice of Texas

FROM SRN NEWS

Roche says divarasib cut risk of death 44% in lung cancer trial

SHARE X Facebook

ZURICH, Oct 25 (Reuters) – Swiss drugmaker Roche said on Sunday its experimental lung cancer drug divarasib reduced the risk of death by 44% compared with existing treatments in a phase III study.

• Roche said patients with previously treated KRAS G12C-mutated non-small cell lung cancer who received divarasib had median overall survival of nearly 18 months, compared with 12 months for those treated with sotorasib or adagrasib

• Divarasib also lowered the risk of disease progression or death by 42%, with median progression-free survival of 9.8 months against 5.7 months in the control group

• The Phase III Krascendo 1 trial involved 338 patients and compared divarasib with the two approved KRAS G12C inhibitors

• The objective response rate was 58% for divarasib, versus 32% for sotorasib or adagrasib

• No new safety findings were observed. Some 4.8% of patients on divarasib stopped treatment because of treatment-related adverse events, versus 11.7% in the control group

• Roche said it was working with health authorities to bring the treatment to patients

• The results were presented at the European Society for Medical Oncology Congress and published in the New England Journal of Medicine

(Writing by Dave Graham; editing by Barbara Lewis)

Brought to you by www.srnnews.com

SRN News — View the original story at SRNNews.com.

LIVE Joe Pags Tap play to listen
0:00 0:00
Show